Matrix metalloproteinase-9 regulates tumor cell invasion through cleavage of protease nexin-1

Cancer Research

Volumn 70, Issue 17, 2010, Pages 6988-6998

  Xu, Danmei ^a,c   McKee, Chad M ^a   Cao, Yunhong ^a   Ding, Yunchuan ^a,c   Kessler, Benedikt M ^b   Muschel, Ruth J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; PROTEASE NEXIN I; UROKINASE; AMYLOID PRECURSOR PROTEIN; CELL SURFACE RECEPTOR; PROTEASE NEXIN; SERINE PROTEINASE INHIBITOR; SERPINE2 PROTEIN, HUMAN; SERPINE2 PROTEIN, MOUSE; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INVASION; CELL INVASION; DOWN REGULATION; ENZYME ACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN TARGETING; TUMOR CELL; ANIMAL; C57BL MOUSE; ENZYMOLOGY; GENETICS; HUMAN; KNOCKOUT MOUSE; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE; TUMOR INVASION;

AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CELL LINE, TUMOR; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; PROTEASE NEXINS; RECEPTORS, CELL SURFACE; RNA, SMALL INTERFERING; SERPIN E2; SERPINS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 77956291596     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0242     Document Type: Article

References (47)

1. Bjorklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta 2005;1755:37-69.
2. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005;438:820-7.
3. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295:2387-92.
4. Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 2009;27:5287-97.
5. Cauwe B, Van den Steen PE, Opdenakker G. The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit Rev Biochem Mol Biol 2007;42:113-85.
6. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
7. Xu D, Suenaga N, Edelmann MJ, Fridman R, Muschel RJ, Kessler BM. Novel MMP-9 substrates in cancer cells revealed by a label-free quantitative proteomics approach. Mol Cell Proteomics 2008;7:2215-28.
8. Sommer J, Gloor SM, Rovelli GF, et al. cDNA sequence coding for a rat glia-derived nexin and its homology to members of the serpin superfamily. Biochemistry 1987;26:6407-10.
9. Baker JB, Low DA, Simmer RL, Cunningham DD. Protease-nexin: a cellular component that links thrombin and plasminogen activator and mediates their binding to cells. Cell 1980;21:37-45.
10. Wagner SL, Lau AL, Nguyen A, et al. Inhibitors of urokinase and thrombin in cultured neural cells. J Neurochem 1991;56:234-42.
11. Duffy MJ, McGowan PM, Gallagher WM. Cancer invasion and metastasis: changing views. J Pathol 2008;214:283-93.
12. Baker JB, Gronke RS. Protease nexins and cellular regulation. Semin Thromb Hemost 1986;12:216-20.
13. Boulaftali Y, Adam F, Venisse L, et al. Anticoagulant and antithrombotic properties of platelet protease nexin-1. Blood 2009;115:97-106.
14. Vaughan PJ, Cunningham DD. Regulation of protease nexin-1 synthesis and secretion in cultured brain cells by injury-related factors. J Biol Chem 1993;268:3720-7.
15. Bouton MC, Richard B, Rossignol P, et al. The serpin protease-nexin 1 is present in rat aortic smooth muscle cells and is upregulated in L-NAME hypertensive rats. Arterioscler Thromb Vasc Biol 2003;23:142-7.
16. Fayard B, Bianchi F, Dey J, et al. The serine protease inhibitor protease nexin-1 controls mammary cancer metastasis through LRP-1-mediated MMP-9 expression. Cancer Res 2009;69:5690-8.
17. Farrell DH, Cunningham DD. Glycosaminoglycans on fibroblasts accelerate thrombin inhibition by protease nexin-1. Biochem J 1987;245:543-50.
18. Donovan FM, Vaughan PJ, Cunningham DD. Regulation of protease nexin-1 target protease specificity by collagen type IV. J Biol Chem 1994;269:17199-205.
19. Silverman GA, Bird PI, Carrell RW, et al. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem 2001;276:33293-6.
20. Gettins PG. Serpin structure, mechanism, and function. Chem Rev 2002;102:4751-804.
21. Conese M, Nykjaer A, Petersen CM, et al. α-2 Macroglobulin receptor/Ldl receptor-related protein(Lrp)-dependent internalization of the urokinase receptor. J Cell Biol 1995;131:1609-22.
22. Strickland DK, Ranganathan S. Diverse role of LDL receptor-related protein in the clearance of proteases and in signaling. J Thromb Haemost 2003;1:1663-70.
23. Crisp RJ, Knauer DJ, Knauer MF. Roles of the heparin and low density lipid receptor-related protein-binding sites of protease nexin 1 (PN1) in urokinase-PN1 complex catabolism. The PN1 heparin-binding site mediates complex retention and degradation but not cell surface binding or internalization. J Biol Chem 2000;275:19628-37.
24. Gao S, Krogdahl A, Sorensen JA, Kousted TM, Dabelsteen E, Andreasen PA. Overexpression of protease nexin-1 mRNA and protein in oral squamous cell carcinomas. Oral Oncol 2008;44:309-13.
25. Selzer-Plon J, Bornholdt J, Friis S, et al. Expression of prostasin and its inhibitors during colorectal cancer carcinogenesis. BMC Cancer 2009;9:201.
26. Dubois B, Masure S, Hurtenbach U, et al. Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J Clin Invest 1999;104:1507-15.
27. Stearns ME, Wang M, Fudge K. Liarozole and 13-cis-retinoic acid anti-prostatic tumor activity. Cancer Res 1993;53:3073-7.
28. Bernhard EJ, Stanbridge EJ, Gupta S, et al. Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines. Cancer Res 2000;60:6597-600.
29. Ding Y, Xu D, Feng G, Bushell A, Muschel RJ, Wood KJ. Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and -9. Diabetes 2009;58:1797-806.
30. Aureli L, Gioia M, Cerbara I, et al. Structural bases for substrate and inhibitor recognition by matrix metalloproteinases. Curr Med Chem 2008;15:2192-222.
31. Kridel SJ, Sawai H, Ratnikov BI, et al. A unique substrate binding mode discriminates membrane type-1 matrix metalloproteinase from other matrix metalloproteinases. J Biol Chem 2002;277:23788-93.
32. Mansuy IM, van der Putten H, Schmid P, Meins M, Botteri FM, Monard D. Variable and multiple expression of protease Nexin-1 during mouse organogenesis and nervous system development. Development 1993;119:1119-34.
33. Antalis TM, Lawrence DA. Serpin mutagenesis. Methods 2004;32:130-40.
34. Tucker HM, Gerard RD. Sequence requirements in the reactive-center loop of plasminogen-activator inhibitor-1 for recognition of plasminogen activators. Eur J Biochem 1996;237:180-7.
35. Knauer MF, Hawley SB, Knauer DJ. Identification of a binding site in protease nexin I (PN1) required for the receptor mediated internalization of PN1-thrombin complexes. J Biol Chem 1997;272:12261-4.
36. Li Y, Cozzi PJ. Targeting uPA/uPAR in prostate cancer. Cancer Treat Rev 2007;33:521-7.
37. Richard B, Pichon S, Arocas V, et al. The serpin protease nexin-1 regulates vascular smooth muscle cell adhesion, spreading, migration and response to thrombin. J Thromb Haemost 2006;4:322-8.
38. Binder BR, Mihaly J. The plasminogen activator inhibitor "paradox" in cancer. Immunol Lett 2008;118:116-24.
39. Bajou K, Peng H, Laug WE, et al. Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis. Cancer Cell 2008;14:324-34.
40. Zou Z, Anisowicz A, Hendrix MJ, et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 1994;263:526-9.
41. Nierodzik ML, Karpatkin S. Thrombin induces tumor growth, metastasis, and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 2006;10:355-62.
42. Ulisse S, Baldini E, Sorrenti S, D'Armiento M. The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr Cancer Drug Targets 2009;9:32-71.
43. Pulukuri SM, Gondi CS, Lakka SS, et al. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem 2005;280:36529-40.
44. Chapman HA, Wei Y. Protease crosstalk with integrins: the urokinase receptor paradigm. Thromb Haemost 2001;86:124-9.
45. Czekay RP, Loskutoff DJ. Plasminogen activator inhibitors regulate cell adhesion through a uPAR-dependent mechanism. J Cell Physiol 2009;220:655-63.
46. Kelly P, Stemmle LN, Madden JF, Fields TA, Daaka Y, Casey PJ. A role for the G12 family of heterotrimeric G proteins in prostate cancer invasion. J Biol Chem 2006;281:26483-90.
47. Menshikov M, Elizarova E, Plakida K, et al. Urokinase upregulates matrix metalloproteinase-9 expression in THP-1 monocytes via gene transcription and protein synthesis. Biochem J 2002;367:833-9.